This infiltrate may be mild and diffuse throughout the gland, but more typically occurs as aggregates of mononuclear cells and even lymphoid germinal centers, referred to as focal thyroiditis
Tirzepatide (Mounjaro, Zepbound) is technically a dual GIP/GLP-1 receptor agonist, hitting two incretin receptors instead of one, which explains its superior weight loss outcomes in clinical trials
The warnings had been in place for more than two decades following the 2002 Womens Health Initiative study, which raised concerns about cardiovascular and cancer risks
In contrast to RCTs, retrospective observational studies offer the benefit of capturing extensive patient data in real-world settings
Mitophagy-related regulated cell death: molecular mechanisms and disease implications
When compared to weight reductions of 14% with semaglutide, 8.4% with liraglutide, 10% with dulaglutide and 15% with tirzepatide in the general population, the authors concluded that the impact of GLP1 agonists may be attenuated in women with breast cancer receiving endocrine therapy [89]